<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2682464-A1" country="EP" doc-number="2682464" kind="A1" date="20140108" family-id="46758102" file-reference-id="258066" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146585826" ucid="EP-2682464-A1"><document-id><country>EP</country><doc-number>2682464</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12752986-A" is-representative="YES"><document-id mxw-id="PAPP154848018" load-source="docdb" format="epo"><country>EP</country><doc-number>12752986</doc-number><kind>A</kind><date>20120302</date><lang>JA</lang></document-id><document-id mxw-id="PAPP204735610" load-source="docdb" format="original"><country>EP</country><doc-number>12752986.5</doc-number><date>20120302</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140553228" ucid="JP-2011046386-A" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2011046386</doc-number><kind>A</kind><date>20110303</date></document-id></priority-claim><priority-claim mxw-id="PPC140551518" ucid="JP-2012055366-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2012055366</doc-number><kind>W</kind><date>20120302</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL2114895596" load-source="docdb">A01K  67/04        20060101ALI20140918BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2114897136" load-source="docdb">A01K  67/033       20060101ALI20140918BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2114897404" load-source="docdb">C12P  21/02        20060101ALI20140918BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2114898828" load-source="docdb">C07K  14/75        20060101ALI20140918BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2114904335" load-source="docdb">C12N  15/09        20060101AFI20140918BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1946289439" load-source="docdb" scheme="CPC">A01K2267/01        20130101 LA20160429BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1946289440" load-source="docdb" scheme="CPC">A01K2227/706       20130101 LA20160429BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1946289441" load-source="docdb" scheme="CPC">A01K2217/052       20130101 LA20160429BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1946289442" load-source="docdb" scheme="CPC">A01K  67/04        20130101 LI20160429BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989625532" load-source="docdb" scheme="CPC">C07K  14/75        20130101 FI20131219BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132362111" lang="DE" load-source="patent-office">TRANSGENE FIBRINOGENPRODUZIERENDE SEIDENRAUPE</invention-title><invention-title mxw-id="PT132362112" lang="EN" load-source="patent-office">FIBRINOGEN-PRODUCING TRANSGENIC SILKWORM</invention-title><invention-title mxw-id="PT132362113" lang="FR" load-source="patent-office">VER À SOIE TRANSGÉNIQUE PRODUISANT DES FIBRINOGÈNES</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919515202" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>IMMUNO BIOLOGICAL LAB CO LTD</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919507272" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.</last-name></addressbook></applicant><applicant mxw-id="PPAR919018873" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Immuno-Biological Laboratories Co., Ltd.</last-name><iid>101417294</iid><address><street>1091-1 Naka Aza-Higashida</street><city>Fujioka-shi Gunma 375-0005</city><country>JP</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919514321" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SEKIGUCHI SATOSHI</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919525233" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SEKIGUCHI, SATOSHI</last-name></addressbook></inventor><inventor mxw-id="PPAR919009709" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>SEKIGUCHI, SATOSHI</last-name><address><street>c/o Bioscience Lab. Central Laboratory NIPPON FLOUR MILLS CO. LTD. 5-1-3 Midorigaoka Atsugi-Shi</street><city>KANAGAWA 243-0041</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919514353" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>TAKAHISA MANABU</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919511130" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>TAKAHISA, Manabu</last-name></addressbook></inventor><inventor mxw-id="PPAR919014100" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>TAKAHISA, Manabu</last-name><address><street>c/o Bioscience Lab. Central Laboratory NIPPON FLOUR MILLS CO. LTD. 5-1-3 Midorigaoka Atsugi-Shi</street><city>Kanagawa 2430041</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919522886" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>TOMITA MASAHIRO</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919542957" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>TOMITA, MASAHIRO</last-name></addressbook></inventor><inventor mxw-id="PPAR919007197" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>TOMITA, MASAHIRO</last-name><address><street>c/o IMMUNO-BIOLOGICAL LABORATORIES CO. LTD. 1091-1 Naka Aza-Higashida Fujioka-Shi</street><city>Gunma 3750005</city><country>JP</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919018685" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Keirstead, Tanis Evelyne</last-name><suffix>et al</suffix><iid>101170729</iid><address><street>Mewburn Ellis LLP 33 Gutter Lane</street><city>London EC2V 8AS</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="JP-2012055366-W"><document-id><country>JP</country><doc-number>2012055366</doc-number><kind>W</kind><date>20120302</date><lang>JA</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012118176-A1"><document-id><country>WO</country><doc-number>2012118176</doc-number><kind>A1</kind><date>20120907</date><lang>JA</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549757930" load-source="docdb">AL</country><country mxw-id="DS549838923" load-source="docdb">AT</country><country mxw-id="DS549911968" load-source="docdb">BE</country><country mxw-id="DS549753694" load-source="docdb">BG</country><country mxw-id="DS549752694" load-source="docdb">CH</country><country mxw-id="DS549911969" load-source="docdb">CY</country><country mxw-id="DS549830298" load-source="docdb">CZ</country><country mxw-id="DS549757931" load-source="docdb">DE</country><country mxw-id="DS549911970" load-source="docdb">DK</country><country mxw-id="DS549911971" load-source="docdb">EE</country><country mxw-id="DS549824633" load-source="docdb">ES</country><country mxw-id="DS549753695" load-source="docdb">FI</country><country mxw-id="DS549753696" load-source="docdb">FR</country><country mxw-id="DS549757932" load-source="docdb">GB</country><country mxw-id="DS549911972" load-source="docdb">GR</country><country mxw-id="DS549757957" load-source="docdb">HR</country><country mxw-id="DS549830299" load-source="docdb">HU</country><country mxw-id="DS549752695" load-source="docdb">IE</country><country mxw-id="DS549911973" load-source="docdb">IS</country><country mxw-id="DS549753701" load-source="docdb">IT</country><country mxw-id="DS549911974" load-source="docdb">LI</country><country mxw-id="DS549753702" load-source="docdb">LT</country><country mxw-id="DS549838924" load-source="docdb">LU</country><country mxw-id="DS549753703" load-source="docdb">LV</country><country mxw-id="DS549753704" load-source="docdb">MC</country><country mxw-id="DS549838925" load-source="docdb">MK</country><country mxw-id="DS549838930" load-source="docdb">MT</country><country mxw-id="DS549753717" load-source="docdb">NL</country><country mxw-id="DS549752696" load-source="docdb">NO</country><country mxw-id="DS549753718" load-source="docdb">PL</country><country mxw-id="DS549824650" load-source="docdb">PT</country><country mxw-id="DS549757958" load-source="docdb">RO</country><country mxw-id="DS549824651" load-source="docdb">RS</country><country mxw-id="DS549753719" load-source="docdb">SE</country><country mxw-id="DS549829856" load-source="docdb">SI</country><country mxw-id="DS549752701" load-source="docdb">SK</country><country mxw-id="DS549752702" load-source="docdb">SM</country><country mxw-id="DS549911975" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128673880" lang="EN" load-source="patent-office"><p id="pa01" num="0001">Disclosed is a novel means that enables mass production of highly safe fibrinogen at low cost. The transgenic silkworm of the present invention expresses the fibrinogen subunit Aα, Bβ and γ chains in the silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament. Preferably, the transgenic silkworm expresses the subunits in the middle silk gland cells and produces fibrinogen in the sericin layer of the cocoon filament. By recovering fibrinogen from the cocoon of the transgenic silkworm of the present invention, highly safe fibrinogen can be mass-produced at low cost.<img id="iaf01" file="imgaf001.tif" wi="76" he="119" img-content="drawing" img-format="tif"/></p></abstract><abstract mxw-id="PA128738160" lang="EN" source="EPO" load-source="docdb"><p>Disclosed is a novel means that enables mass production of highly safe fibrinogen at low cost. The transgenic silkworm of the present invention expresses the fibrinogen subunit A±, B² and ³ chains in the silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament. Preferably, the transgenic silkworm expresses the subunits in the middle silk gland cells and produces fibrinogen in the sericin layer of the cocoon filament. By recovering fibrinogen from the cocoon of the transgenic silkworm of the present invention, highly safe fibrinogen can be mass-produced at low cost.</p></abstract><description mxw-id="PDES63959868" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">TECHNICAL FIELD</heading><p id="p0001" num="0001">The present invention relates to a transgenic silkworm that produces fibrinogen having coagulation activity in the cocoon filament, a method for producing the silkworm, and a method for producing fibrinogen.</p><heading id="h0002">BACKGROUND ART</heading><p id="p0002" num="0002">Fibrinogen is a plasma protein present in blood plasma, and is a glycoprotein with a molecular weight of 340 kDa. Fibrinogen has a hexameric molecular structure wherein three chains, that is, the Aα chain, Bβ chain and γ chain, are bound to one another via disulfide bonds and the resulting complex forms a dimer (Aα-Bβ-γ)<sub>2</sub>. The Aα chain, with a size of 67 kDa, is composed of 610 amino acid residues and does not have a sugar chain. The Bβ chain, with a size of 56 kDa, is composed of 461 amino acid residues and has a sugar chain at Asn at position 364. The γ chain, with a size of 48 kDa, is composed of 411 amino acid residues and has a sugar chain at Asn at position 52.</p><p id="p0003" num="0003">Fibrinogen is involved in blood coagulation. In the living body, thrombin cleaves the Aα and Bβ chains of fibrinogen to remove the fibrinopeptide A and the fibrinopeptide B, thereby converting fibrinogen into (α-β-γ)<sub>2</sub> (fibrinomonomer). The fibrinomonomer is polymerized in the presence of Ca<sup>2+</sup> to form a fibrin polymer. Further, upon activation of blood coagulation factor XIII by thrombin, the transglutaminase activity of the factor causes formation of peptide bonds among fibrin polymers, to form strongly cross-linked fibrin.<!-- EPO <DP n="2"> --></p><p id="p0004" num="0004">The fibrinogen currently used in the medical field is manufactured by separation and purification from human blood plasma. Since human blood plasma is used as a raw material, there is the risk of contamination with viruses, so that a process such as inactivation of sources of infection is indispensable. Furthermore, since supply of human plasma as a raw material is dependent on blood donation, its constant and stable supply is not always easy.</p><p id="p0005" num="0005">By production of fibrinogen using gene recombination technology, safe fibrinogen can be stably provided. Such attempts have been reported several times so far, but none of them succeeded in providing a sufficiently efficient and satisfactory method. For example, in Patent Document 1 and Non-patent Document 1, a method for producing a recombinant fibrinogen using a <i>Pichia</i> yeast has been disclosed, but, in this method, fibrinogen secreted into the culture liquid is degraded by protease, so that the production method is not efficient. Patent Documents 2 and 3 disclose a method for producing a recombinant fibrinogen using animal cultured cells. However, the production is too costly and laborious to realize commercial production of fibrinogen since, for example, large-scale facilities for cell culture and control of the culture density are required. Further, since animal cells are used, there is the risk of contamination with animal-derived substances and infectious viruses, so that the method has the same problem as the current method wherein fibrinogen is manufactured from human blood.</p><heading id="h0003">PRIOR ART DOCUMENTS</heading><heading id="h0004">PATENT DOCUMENTS</heading><p id="p0006" num="0006"><ul><li>Patent Document 1: <patcit id="pcit0001" dnum="JP2004016055A"><text>JP 2004-16055 A</text></patcit></li><li>Patent Document 2: <patcit id="pcit0002" dnum="JP4573775B"><text>JP 4573775 B</text></patcit><!-- EPO <DP n="3"> --></li><li>Patent Document 3: <patcit id="pcit0003" dnum="JP2009528843A"><text>JP 2009-528843 A</text></patcit></li></ul></p><heading id="h0005">NON-PATENT DOCUMENTS</heading><p id="p0007" num="0007">Non-patent Document 1: <nplcit id="ncit0001" npl-type="s"><text>Protein Expression and Purification 59 (2008) 289-296</text></nplcit></p><heading id="h0006">SUMMARY OF THE INVENTION</heading><heading id="h0007">PROBLEMS TO BE SOLVED BY THE INVENTION</heading><p id="p0008" num="0008">Accordingly, the present invention aims to provide a novel means that enables mass production of highly safe fibrinogen at low cost.</p><heading id="h0008">MEANS FOR SOLVING THE PROBLEMS</heading><p id="p0009" num="0009">The present inventors arrived at the idea of producing fibrinogen by a known recombinant protein production technique using a silkworm, and attempted to express the genes for the Aα chain, Bβ chain and γ chain of fibrinogen in the silk glands of a silkworm and then to recover fibrinogen from the cocoon. They tried to prepare a silkworm expressing the Bβ chain and a silkworm expressing the Aα chain and the γ chain and then to cross them to obtain a silkworm expressing the three chains, but no secretion of the Bβ chain into the cocoon could be found in the Bβ chain-expressing silkworm. However, when this Bβ chain-expressing silkworm was crossed with the Aα chain/γ chain-expressing silkworm, fibrinogen having coagulation activity was successfully secreted into the cocoon filament. Further, the present inventors found conditions where fibrinogen can be efficiently recovered from the cocoon filament, thereby completing the present invention.</p><p id="p0010" num="0010">That is, the present invention provides a transgenic silkworm which expresses fibrinogen subunit Aα, Bβ and γ chains in silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament. The present invention also<!-- EPO <DP n="4"> --> provides a silkworm cocoon produced by the transgenic silkworm according to the present invention, said silkworm cocoon comprising fibrinogen having coagulation activity. The present invention further provides a method for producing fibrinogen, said method comprising recovering fibrinogen from the cocoon of the transgenic silkworm according to the present invention. The present invention further provides a method for preparing a transgenic silkworm that produces fibrinogen having coagulation activity in the cocoon filament, said method comprising: introducing the fibrinogen subunit Aα, Bβ and γ genes each functionally linked to a promoter that functions in silk gland cells into silkworms; and selecting a silkworm that expresses the Aα, Bβ and γ chains in silk gland cells.</p><heading id="h0009">EFFECT OF THE INVENTION</heading><p id="p0011" num="0011">By the present invention, a transgenic silkworm that secretes fibrinogen having coagulation activity into the cocoon filament was provided for the first time. In particular, expression of the Aα, Bβ and γ genes in the middle silk gland is advantageous for recovery of active fibrinogen since fibrinogen is secreted into the sericin layer, which is a relatively water-soluble part in the cocoon filament. Silkworms are organisms having high protein synthetic capacity, and can be easily kept. Unlike production of fibrinogen from a blood material collected by blood donation, the risk of contamination with viruses can be eliminated. By the present invention, highly safe fibrinogen can be mass-produced at low cost.</p><heading id="h0010">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p0012" num="0012"><ul><li><figref idrefs="f0001">Fig. 1</figref> shows a construction diagram for the vector used for preparation of the Bβ-introduced silkworm in Examples.</li><li><figref idrefs="f0002">Fig. 2</figref> shows a construction diagram for the vector used for preparation of the Aα/γ-introduced silkworm in Examples.<!-- EPO <DP n="5"> --></li><li><figref idrefs="f0003">Fig. 3</figref> shows a construction diagram for the vector used for preparation of the Aα/γ-introduced silkworm in Examples (continued from <figref idrefs="f0002">Fig. 2</figref>).</li><li><figref idrefs="f0004">Fig. 4</figref> shows an example of the results of detection, by Western blotting, of the subunit proteins in the cocoon filaments of the Bβ-introduced silkworm and the Aα/γ-introduced silkworm prepared in Examples.</li><li><figref idrefs="f0004">Fig. 5</figref> shows an example of the results of investigation, by Western blotting, of expression of the Bβ chain in the silk glands of the Bβ-introduced silkworm prepared in Examples.</li><li><figref idrefs="f0005">Fig. 6</figref> shows CBB (Coomassie brilliant blue) staining of electrophoresed proteins contained in the cocoon filament of the transgenic silkworms prepared in Examples.</li><li><figref idrefs="f0006">Fig. 7</figref> is an electrophoretic profile showing an increased amount of each subunit of fibrinogen accumulated in the cocoons of transgenic silkworms into which transactivator IE1 has been introduced.</li><li><figref idrefs="f0007">Fig. 8</figref> is an electrophoretic profile showing influence of differences in the expression level of transactivator IE1 on the expression levels (amounts accumulated in the cocoon filament) of the subunits.</li><li><figref idrefs="f0008">Fig. 9</figref> shows the results of investigation on the conditions for extraction of fibrinogen from cocoon filaments using the cocoons of transgenic silkworms into which transactivator IE1 has not been introduced.</li><li><figref idrefs="f0009">Fig. 10</figref> shows the results of investigation on the conditions for extraction of fibrinogen from cocoon filaments using the cocoons of transgenic silkworms into which transactivator IE1 has been introduced.</li></ul></p><heading id="h0011">MODE FOR CARRYING OUT THE INVENTION</heading><p id="p0013" num="0013">The transgenic silkworm of the present invention expresses the three subunits of fibrinogen, the Aα chain, Bβ chain and γ chain, in silk gland cells. A silk gland<!-- EPO <DP n="6"> --> is an organ that synthesizes and secretes silk threads, and expression of a recombinant protein in silk gland cells causes secretion of the protein together with silk threads, resulting in accumulation of the protein in the cocoon. The silk gland can be divided into three parts, the anterior part, the middle part and the posterior part. Fibroin is secreted from the posterior part, and sericin is secreted from the middle part. The central portion of the silk thread is constituted by figroin, and covered with sericin. Expression of the subunit genes in the posterior silk gland causes secretion of fibrinogen into the fibroin layer of the cocoon filament, and expression of the subunit genes in the middle silk gland causes secretion of fibrinogen into the sericin layer. Since the recombinant protein secreted into the sericin layer can be easily dissolved by immersion of the cocoon filament in water or an aqueous buffer, the protein can be easily recovered from the cocoon while its activity is maintained. Hence, it is preferred that the transgenic silkworm of the present invention express the three subunit genes in the middle silk gland.</p><p id="p0014" num="0014">Amino acid sequences of human fibrinogen and base sequences encoding them are known, and registered in GenBank under the accession numbers of, for example, NM_021871 (Aα chain), NM_005141 (Bβ chain) and NM_000509 (γ chain). These known sequences are shown in SEQ ID NOs:1 and 2 (cDNA sequence and amino acid sequence of the Aα chain), SEQ ID NOs:5 and 6 (cDNA sequence and amino acid sequence of the Bβ chain) and SEQ ID NOs:9 and 10 (cDNA sequence and amino acid sequence of the γ chain), respectively. The Aα, Bβ, and γ genes to be incorporated into a vector(s) for transformation of a silkworm can be easily obtained by appropriately designing primers based on known sequence information also described in SEQUENCE LISTING of the present application and amplifying the genes from a human cDNA library by conventional PCR.</p><p id="p0015" num="0015"><!-- EPO <DP n="7"> --> When the fibrinogen subunit genes are introduced into a silkworm, the original signal peptide region of each subunit is preferably replaced with the signal peptide region of human calreticulin. Since the signal peptide of human calreticulin functions well in silk gland cells of a silkworm, it is advantageous for efficient secretion of a recombinant fibrinogen into the cocoon filament. The cDNA sequence and the amino acid sequence of each subunit whose signal peptide was replaced with the signal peptide of human calreticulin are shown in SEQ ID NOs:3 and 4 (Aα chain), SEQ ID NOs:7 and 8 (Bβ chain) and SEQ ID NOs:11 and 12 (γ chain), respectively. The region encoding the signal peptide of human calreticulin corresponds to 64 nt to 111 nt of SEQ ID NO:3. Each of the base sequences shown in SEQ ID NOs:3, 7 and 11 comprises sequences for incorporation into a vector (e.g., a restriction enzyme recognition site) and BmNPV polyhedrin 5'-UTR (11 nt to 60 nt of SEQ ID NO:3) that was added for the purpose of promoting translation. Such modification of a sequence can be easily carried out by PCR using a primer having the desired additional sequence. Its specific procedure is as described in detail in Examples below.</p><p id="p0016" num="0016">Examples of the procedure for introducing the three subunit genes into a silkworm include a procedure in which the three genes are introduced at the same time, a procedure in which a silkworm into which any one of the three genes has been introduced is crossed with a silkworm into which the other two genes have been introduced at the same time, and a procedure in which silkworms each prepared by introducing a single gene are sequentially crossed. In cases where a plurality of genes are introduced at the same time, the plurality of genes may be incorporated into a single vector, or a plurality of vectors each carrying a single gene may be introduced at the same time to a silkworm. In the Examples below, a vector carrying only the Bβ gene and a vector carrying 2 genes, the Aα gene and the γ gene,<!-- EPO <DP n="8"> --> were constructed to obtain a Bβ-introduced silkworm and an Aα/γ-introduced silkworm, and these silkworms were crossed to obtain an Aα/Bβ/γ-introduced silkworm. However, the method of introduction of the three genes is not limited thereto.</p><p id="p0017" num="0017">In order to express the fibrinogen subunits in the silk gland, the Aα, Bβ and γ genes may be introduced into a silkworm in a state where these genes are each functionally linked to a promoter that functions in silk gland cells. The term "functionally linked" herein means that each gene sequence is linked to the downstream region of the promoter such that the gene is under the control of the promoter. The promoter that functions in silk gland cells may be any one as long as it initiates expression of a gene downstream thereof in silk gland cells, and may be a promoter that also functions in other tissues/cells. The promoter that specifically functions in the silk gland cells of interest is preferred. Preferred examples of the promoter that functions in the middle silk gland include those of the sericin genes (e.g., sericin 1 gene and sericin 2 gene), and preferred examples of the promoter that functions in the posterior silk gland include promoters of the fibroin heavy chain gene, fibroin light chain gene and fibrohexamerin gene. However, the promoter is not limited to these. In the present invention, it is preferred that the fibrinogen subunit genes be expressed in the middle silk gland, and therefore a promoter that functions in the middle silk gland, such as the sericin gene promoter, is preferably used.</p><p id="p0018" num="0018">In view of increasing the expression levels, the three subunit genes are preferably introduced in combination with an enhancer(s). The enhancer, a <i>cis-</i>element of transcription regulation, is provided in the vicinity of a promoter(s) and a subunit gene(s). The enhancer may be located either upstream or downstream of the<!-- EPO <DP n="9"> --> promoter(s) and the subunit gene(s), and is usually placed upstream of the promoter(s). Further, since a single enhancer can promote transcription of a plurality of genes in its vicinity, a single enhancer may be combined with, for example, two sets of the promoter + subunit gene. For example, in the specific example of the gene transfer vector shown in <figref idrefs="f0003">Fig. 3</figref>, one enhancer is inserted for two subunit genes. The enhancer is not limited as long as it is capable of enhancing the transcription activity of a promoter(s) employed, and those skilled in the art can appropriately evaluate the effect of enhancers to enhance the transcription activity using a transient expression system, and select a preferred enhancer. Preferred specific examples of the enhancer which may be used in the present invention include the homologous region of baculoviruses, and hr3 derived from BmNPV may be especially preferably used (see <patcit id="pcit0004" dnum="JP4271122B"><text>JP 4271122 B</text></patcit>). Since sequences of baculovirus-derived enhancers such as hr3 are known (e.g., GenBank NC_001962 and NC_001623) and since the enhancers are also used in commercially available expression vectors for insect cells and the like, the enhancer can be easily obtained by PCR amplification from a baculovirus genome or a commercially available vector as appropriate.</p><p id="p0019" num="0019">Similarly, in view of increasing the expression levels, the three subunits are preferably introduced in combination with a transactivator(s). A transactivator is a factor that directly or indirectly acts on a promoter to activate transcription of a gene. A transactivator and a subunit gene(s) may be inserted into the same vector and introduced at the same time, or a transactivator may be introduced into a silkworm separately from the subunit genes. For example, the transactivator gene may be inserted into a vector which is different from the vector(s) containing the subunit genes, and the resulting vector may be introduced into a silkworm together with the vector(s) containing the subunit genes. Alternatively, an Aα/Bβ/γ-introduced<!-- EPO <DP n="10"> --> silkworm may be prepared in advance by introduction of the three subunit genes, and the transactivator gene may be then introduced into this silkworm by a genetic engineering method or by crossing with a transactivator-expressing silkworm which has been separately prepared. The term "introducing a subunit gene(s) in combination with a transactivator(s)" includes all of these modes. The transactivator is not limited as long as it can increase the action of a promoter(s) to be employed (or an enhancer(s) to be employed in cases of a transactivator that acts on an enhancer(s)) on the transcription. Those skilled in the art can appropriately evaluate the activity using a transient expression system to select a preferred transactivator. Preferred specific examples of the transactivator which may be used in the present invention include transcription factor IE1 derived from a baculovirus (see <patcit id="pcit0005" dnum="JP4271122B"><text>JP 4271122 B</text></patcit>). When introducing a transactivator into a silkworm by a genetic engineering method, the same promoter as the one used for the fibrinogen subunit gene(s) may be used. Since sequences of the IE1 gene are also known (e.g., GenBank AY048770 and M16820) and the gene is also used in commercially-available expression vectors for insect cells and the like, the gene can be easily obtained by PCR amplification from a baculovirus genome or a commercially available vector, as appropriate. Further, as was used in the Examples below, IE1-expressing silkworm strains are known (<nplcit id="ncit0002" npl-type="s"><text>FEBS Journal 276, 5806-5820 (2009</text></nplcit>), <nplcit id="ncit0003" npl-type="s"><text>Biotechnol Bioeng 106, 860-870 (2010</text></nplcit>)).</p><p id="p0020" num="0020">More preferably, both an enhancer(s) and a transactivator(s) are introduced in combination with the fibrinogen subunit genes. As described in the Examples below, when the IE1 gene is introduced into an Aα/Bβ/γ-introduced silkworm (in which hr3 is used as an enhancer), the weight of the cocoon decreases depending on the expression level of IE1, but the expression levels of the three fibrinogen subunits largely increase and their contents in the cocoon filament also largely increase, and as<!-- EPO <DP n="11"> --> a consequence, the production efficiency of fibrinogen can be further improved.</p><p id="p0021" num="0021">In the present invention, the term "introduced in combination" means that an enhancer(s) and/or a transactivator(s) is/are introduced into a silkworm such that the introduced enhancer(s) and/or transactivator(s) contribute(s) to increased expression of the fibrinogen subunit gene(s) in silk gland cells. In cases where an enhancer is introduced in combination with the subunit gene(s), the enhancer is introduced such that it is present in the vicinity of the promoter(s) and the subunit gene(s). Usually, the enhancer is incorporated in the vicinity of a subunit gene(s) in a gene transfer vector, and then introduced into a silkworm together with the subunit gene(s). As described above, unlike the enhancer, the transactivator does not need to be positioned in the vicinity of a subunit gene(s). Therefore, when the term "transactivator is introduced in combination with a subunit gene(s)" is mentioned, it includes the above-described modes, for example, a mode wherein a transactivator is subsequently introduced into a transgenic silkworm that expresses the three subunit genes.</p><p id="p0022" num="0022">The method per <i>se</i> for introducing a foreign gene into a silkworm is known, and various vectors for transformation of silkworms are also known (e.g., <nplcit id="ncit0004" npl-type="s"><text>Nature Biotechnology. 21, 52-56, 2003</text></nplcit>; <nplcit id="ncit0005" npl-type="s"><text>J Biosci Bioeng 105, 595-603 (2008</text></nplcit>); <nplcit id="ncit0006" npl-type="s"><text>FEBS Journal 276, 5806-5820 (2009</text></nplcit>); <patcit id="pcit0006" dnum="JP2002306167A"><text>JP 2002-306167 A</text></patcit> and <patcit id="pcit0007" dnum="JP2008067612A"><text>JP 2008-67612 A</text></patcit>). Vectors commonly used for transformation of silkworms at present are vectors using DNA transposons derived from insects, and the most representative example thereof is a plasmid vector using piggyBac. The plasmid vector contains two inverted repeats that are present at both ends of the transposon piggyBac. The sequence to be incorporated into the silkworm chromosome is inserted between the repeats. Microinjection of the resulting vector into a silkworm egg together with a<!-- EPO <DP n="12"> --> transposase-expressing helper plasmid causes transposition of the region between the repeats by the action of transposase, so that a silkworm comprising the region incorporated into its chromosome can be obtained. Also for preparation of the transgenic silkworm of the present invention, such a piggyBac vector may be preferably used. However, the method to be used is not limited thereto, and any known method may be used.</p><p id="p0023" num="0023">For convenience in selection, the vector for transformation of a silkworm usually contains a marker gene which is to be incorporated into the silkworm chromosome together with the subunit gene(s). The expression of the transgene(s) can be indirectly confirmed by observing expression of a marker gene in the silkworm individual (egg, larva or adult) into which the vector has been introduced. Thus, a transgenic silkworm may be selected based on the expression of a marker gene. In the method for preparing a transgenic silkworm of the present invention, the step of "selecting a silkworm that expresses the Aα chain, Bβ chain and γ chain in silk gland cells" may be such a step wherein the expression of the subunit genes is indirectly confirmed by the expression of a marker gene(s), thereby carrying out the selection.</p><p id="p0024" num="0024">The marker is preferably a marker which can be detected, without chemical treatment or mechanical treatment, while the silkworm is kept alive. Preferred examples of the marker that may be used include fluorescent proteins. In cases where, as described in the Examples below, the three subunit genes are divided into two groups to prepare two types of transgenic silkworms and these silkworms are crossed to obtain a silkworm into which the three genes have been introduced, the genes for two kinds of fluorescent proteins whose fluorescence wavelengths are different from each other may be used to prepare the two types of silkworms. For<!-- EPO <DP n="13"> --> example, in cases where a red fluorescent protein is used as one of the markers and a green fluorescent protein is used as the other marker, yellow fluorescence generated by the combination of red fluorescence and green fluorescence can be observed in the silkworm into which both markers have been introduced by the crossing. Thus, using the yellow fluorescence as an indicator, a silkworm into which the three genes have been introduced can be selected.</p><p id="p0025" num="0025">The vector construction diagrams shown in <figref idrefs="f0001 f0002 f0003">Figs. 1 to 3</figref> illustrate the vectors used for preparation of the transgenic silkworm in the Examples below. pMSG-1.1R and pMSG1.1MG used are known as vectors which allow a desired recombinant protein to be secreted into the sericin layer in silkworms (<nplcit id="ncit0007" npl-type="s"><text>J Biosci Bioeng 105, 595-603 (2008</text></nplcit>); <nplcit id="ncit0008" npl-type="s"><text>FEBS Journal 276, 5806-5820 (2009</text></nplcit>)). These vectors contain the enhancer hr3 and the sericin 1 promoter Pser, and an <i>Nru</i>I site for insertion of a foreign gene cDNA is present between the Pser and the silkworm fibroin L-chain poly(A) addition signal FLpA (see <figref idrefs="f0001">Fig. 1</figref> and <figref idrefs="f0002">Fig. 2</figref>). pMSG3.1MG in <figref idrefs="f0003">Fig. 3</figref> is a vector prepared by modifying pMSG1.1MG such that two subunit genes can be introduced thereinto, and comprises the <i>Eco</i>47III site within the second Pser + FLpA as a site for insertion of the second subunit gene. As a marker for gene transfer, a sequence encoding a fluorescent protein (DsRed, GFP) is incorporated downstream of the promoter 3xP3 such that the sequence is functionally linked to the promoter. Since 3xP3 is a promoter that functions in eyes and nervous systems, a transgenic silkworm can be easily selected based on the presence/absence of the fluorescence from these tissues.</p><p id="p0026" num="0026">The thus constructed vector can be microinjected into a silkworm egg together with a transposase-expressing helper plasmid by the method specifically described in the Examples below. The helper plasmid to be used may be any one as<!-- EPO <DP n="14"> --> long as it can express transposase from the plasmid in a silkworm egg, and a known plasmid such as pHA3PIG (<nplcit id="ncit0009" npl-type="s"><text>Nat. Biotechnol. 18, 81-84 (2000</text></nplcit>)) used in the Examples below may be used as the helper plasmid. The vector and the helper plasmid are usually mixed together at a ratio of about 1:1 for use in the injection. The vector and the helper plasmid may be added to an injection buffer (e.g., a buffer comprising 0.5 mM phosphate buffer pH 7.0 and 5 mM KCl) such that each of them is contained at a concentration of about 200 µg/ml, and the resulting mixture may be injected into silkworm eggs at the preblastoderm stage, i.e. 2 to 8 hours after spawning, in a liquid volume of about 15 to 20 nl/egg.</p><p id="p0027" num="0027">The F0 generation hatched from the egg after the injection is crossed with the same F0 generation or with the wild-type strain to obtain F1. When the F1 eggs before hatching or the hatched F1 larvae are irradiated with the excitation light, fluorescence from the marker fluorescent protein can be observed in the eyes and the nervous system in the eggs or larvae comprising the genes introduced thereinto, and thus such individuals can be selected. Incorporation of the subunit genes into the silkworm genome may be finally confirmed by PCR, Southern blotting and/or the like. Individuals showing sufficiently high levels of expression of the subunit proteins may be further selected as appropriate by observing the expression levels of the subunit genes in the silk gland cells or the amounts of the subunit proteins secreted into the cocoon filament by a conventional method.</p><p id="p0028" num="0028">In cases where three transgenic silkworm strains expressing Aα, Bβ and γ, respectively, are prepared, the transgenic silkworm of the present invention into which the three genes have been introduced can be obtained by sequential crossing of these three strains. In cases where a silkworm strain into which one gene has been introduced and a silkworm strain into which the other two genes have been<!-- EPO <DP n="15"> --> introduced are prepared, the transgenic silkworm of the present invention into which the three genes have been introduced can be obtained by crossing the two strains.</p><p id="p0029" num="0029">The cocoon of the transgenic silkworm of the present invention comprises active fibrinogen hexamer composed of the three subunits. Formation of the hexamer can be confirmed based on its size observed by electrophoresis under a nonreducing condition. By recovering fibrinogen from the cocoon, a large amount of safe fibrinogen can be obtained without a danger of contamination with viruses etc. that can infect human. In cases where the subunit genes are expressed in the posterior silk gland to allow fibrinogen to be secreted into the fibroin layer of the cocoon filament, the fibrinogen can be recovered by dissolving the fibroin. For dissolution of the fibroin, a chaotropic salt such as lithium thiocyanate, guanidine thiocyanate or lithium bromide; a mixture of calcium chloride and ethanol; or the like is used. In cases where the subunit genes are expressed in the middle silk gland to allow fibrinogen to be secreted into the sericin layer of the cocoon filament, the fibrinogen can be easily extracted by immersing the cocoon filament in an aqueous buffer since the sericin layer is relatively soluble in water. The extraction from the cocoon filament may be carried out by immersing the cocoon as it is in an extraction liquid, or by immersing the cocoon after cutting, pulverization or the like as appropriate.</p><p id="p0030" num="0030">The fibrinogen secreted into the sericin layer can be extracted and recovered basically by only immersion in an aqueous buffer. Examples of especially preferred extraction conditions include extraction in a buffer containing 1 to 4 M urea, 25 to 100 mM Tris-HCl (pH 6.5 to 8.5), 0.01 to 2.0% surfactant and 0 to 0.25 M NaCl at a low temperature of about 4°C to 10°C for about 10 hours to 24 hours, preferably about 12 hours to 18 hours. Such a condition enables efficient extraction of<!-- EPO <DP n="16"> --> fibrinogen while suppressing elution of sericin, and provides a state advantageous for the later purification steps. The urea concentration is more preferably 1 to 3 M. As a surfactant, polyoxyethylene octylphenyl ether (trade name Triton X-100), polyethylene glycol-p-octylphenyl ether (trade name NP-40), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (trade name CHAPS) and the like may be used, and a mixture of two or more surfactants may also be used. The NaCl concentration in the buffer is preferably low, and may be not more than 0.1 M, or not more than 0.01 M.</p><p id="p0031" num="0031">The fibrinogen eluted into the buffer can be obtained as a concentrated fibrinogen solution by carrying out ultrafiltration and buffer exchange as appropriate, and removal of the precipitates if necessary. As described in the Examples below, when the fibrinogen recovered from the cocoon of the transgenic silkworm of the present invention in the above-described manner is mixed with thrombin and the reaction is allowed to proceed at 37°C for 1 hour, an increase in the viscosity of the reaction liquid is observed, which confirms that the recovered fibrinogen has coagulation activity.</p><heading id="h0012">EXAMPLES</heading><p id="p0032" num="0032">The present invention is described below in more detail by way of Examples. However, the present invention is not limited to the Examples below. In the Examples below and the drawings, "Aα chain" is also simply referred to as "α chain", and "Bβ chain" is also simply referred to as "β chain".</p><heading id="h0013">1. Preparation of Human Fibrinogen cDNA Fragment</heading><p id="p0033" num="0033">cDNA fragments of the three subunits of fibrinogen, Aα, Bβ and γ, were amplified by PCR from a cDNA library of human liver. Replacement of the signal<!-- EPO <DP n="17"> --> sequence, addition of the initiation codon ATG and addition of the UTR sequence were sequentially carried out while subcloning was carried out as appropriate, thereby preparing each subunit cDNA fragment to be inserted into an expression vector for the silkworm middle silk gland. The preparation of the cDNA fragment for each subunit is described in detail below. The PCR reaction was carried out in a volume of 50 µl using 5 units of Ex Taq or 1 unit of KOD.</p><heading id="h0014">(1) Obtaining Aα-chain cDNA</heading><p id="p0034" num="0034">From the cDNA library, an Aα-chain cDNA fragment (hereinafter referred to as Alpha) was amplified under the following reaction conditions. The first PCR product was subjected to electrophoresis in agarose gel, and the band that was assumed to correspond to Alpha was recovered and purified from the gel. The purified product was used as a template in the second PCR.
<tables id="tabl0001" num="0001"><table frame="topbot"><title>[Table 1]</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">First PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>Ex Taq (TAKARA)</entry></row><row><entry>Template</entry><entry>cDNA Library (Plasmid DNA) Human Liver (TAKARA Code No. 9505) (200 ng)</entry></row><row><entry>Primers</entry><entry>alpha Bam1 F1(SEQ ID NO:13) (10 pmoles)</entry></row><row><entry/><entry>alpha Hind3 R1(SEQ ID NO:14) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>94°C 5 min → (94°C 2 min → 50°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">Second PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>Ex Taq</entry></row><row><entry>Template</entry><entry>Purified first PCR product (10 ng)</entry></row><row><entry>Primers</entry><entry>alpha Bam1 F2 (SEQ ID NO:15) (10 pmoles)</entry></row><row><entry/><entry>alpha Hind3 R2 (SEQ ID NO:16) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>94°C 5 min → (94°C 2 min → 50°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup></table></tables></p><p id="p0035" num="0035">The second PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Alpha was recovered and purified from<!-- EPO <DP n="18"> --> the gel, followed by insertion of the purified product into the <i>Bam</i>HI-<i>Hin</i>dIII site of pBluescriptII SK+. The base sequence of the insert was confirmed, and the plasmid was designated pSK-alpha.</p><p id="p0036" num="0036">Subsequently, modification of the signal sequence of Alpha was carried out. In order to obtain a sequence wherein the 15 amino acids at the C-terminus is absent as in the mature form, a reverse primer Fibrinogen Alpha C1 was designed at the position corresponding to the position in the mature form. The first PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Alpha was recovered and purified from the gel. The purified product was used as a template in the second PCR.
<tables id="tabl0002" num="0002"><table frame="topbot"><title>[Table 2]</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="130mm"/><thead><row><entry valign="top">First PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD (TOYOBO)</entry></row><row><entry>Template</entry><entry>pSK-alpha (200 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen Alpha N1(SEQ ID NO:17) (10 pmoles)</entry></row><row><entry/><entry>Fibrinogen Alpha C1(SEQ ID NO:18) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="130mm"/><thead><row><entry valign="top">Second PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>Purified first PCR product (10 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen ATG N2 (SEQ ID NO:19) (10 pmoles)</entry></row><row><entry/><entry>Fibrinogen Alpha C1 (SEQ ID NO:18) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5 min → (96°C 2 min → 55°C 2 min → 724°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup></table></tables></p><p id="p0037" num="0037">The second PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Alpha was recovered and purified from the gel. Using Ex Taq, A was added to the 3'-end of the purified second PCR product, and the product was ligated into pCR2.1-TOPO. The base sequence of the insert was confirmed, and the plasmid was designated pCR-ATGalpha.<!-- EPO <DP n="19"> --></p><p id="p0038" num="0038">Subsequently, addition of a UTR sequence was carried out as follows. The first PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Alpha was recovered and purified from the gel. The purified product was used as a template in the second PCR.
<tables id="tabl0003" num="0003"><table frame="topbot"><title>[Table 3]</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">First PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>pCR-ATGalpha (200 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen UTR N3 (SEQ ID NO:20) (10 pmoles)</entry></row><row><entry/><entry>Fibrinogen Alpha C1 (SEQ ID NO:18) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5 min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">Second PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>Purified first PCR product (10 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen UTR N4 (SEQ ID NO:21) (10 pmoles)</entry></row><row><entry/><entry>Fibrinogen Alpha C1 (SEQ ID NO:18) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5 min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup></table></tables></p><p id="p0039" num="0039">The second PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Alpha was recovered and purified from the gel. This purified fragment was ligated into pENTR/D-TOPO, which was a vector for incorporation into the silkworm expression vector. The base sequence of the insert was confirmed, and the plasmid was designated pENTR-UTRalpha.</p><heading id="h0015">(2) Obtaining Bβ-chain cDNA</heading><p id="p0040" num="0040">From the cDNA library, a Bβ-chain cDNA fragment (hereinafter referred to as Beta) was amplified under the following reaction conditions. The first PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Beta was recovered and purified from the gel. The purified product<!-- EPO <DP n="20"> --> was used as a template in the second PCR.
<tables id="tabl0004" num="0004"><table frame="topbot"><title>[Table 4]</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="128mm"/><thead><row><entry valign="top">First PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>Ex Taq</entry></row><row><entry>Template</entry><entry>cDNA Library (Plasmid DNA) Human Liver (TAKARA Code No. 9505) (200 ng)</entry></row><row><entry>Primers</entry><entry>beta EcoR1 F1(SEQ ID NO:22) (10 pmoles)</entry></row><row><entry/><entry>beta Xho1 R1(SEQ ID NO:23) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>94°C 5 min → (94°C 2 min → 50°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="128mm"/><thead><row><entry valign="top">Second PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>Ex Taq</entry></row><row><entry>Template</entry><entry>Purified first PCR product (10 ng)</entry></row><row><entry>Primers</entry><entry>beta EcoR1 F2 (SEQ ID NO:24) (10 pmoles)</entry></row><row><entry/><entry>beta Xho1 R2 (SEQ ID NO:25) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>94°C 5 min → (94°C 2 min → 50°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup></table></tables></p><p id="p0041" num="0041">The second PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Beta was recovered and purified from the gel. The purified product was inserted into the <i>Eco</i>RI<i>-Xho</i>I site of pBluescriptII SK+. The base sequence of the insert was confirmed, and the plasmid was designated pSK-beta.</p><p id="p0042" num="0042">Subsequently, modification of the signal sequence of Beta was carried out. The first PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Beta was recovered and purified from the gel. The purified product was used as a template in the second PCR.<!-- EPO <DP n="21"> -->
<tables id="tabl0005" num="0005"><table frame="topbot"><title>[Table 5]</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">First PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>pSK-beta (200 ng)</entry></row><row><entry>Primers</entry><entry>Beta-ATG N2 (SEQ ID NO:26) (10 pmoles)</entry></row><row><entry/><entry>Beta-C (SEQ ID NO:27) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">Second PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>Purified first PCR product (10 ng)</entry></row><row><entry>Primers</entry><entry>Beta-ATG N (SEQ ID NO:28) (10 pmoles)</entry></row><row><entry/><entry>Beta-C (SEQ ID NO:27) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5 min → (96°C 2 min → 55°C 2 min →72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup></table></tables></p><p id="p0043" num="0043">The second PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Beta was recovered from the gel. Using Ex Taq, A was added to the 3'-end of the purified second PCR product, and the product was ligated into pCR2.1-TOPO. The base sequence of the insert was confirmed, and the plasmid was designated pCR-ATGbetat.</p><p id="p0044" num="0044">Subsequently, addition of a UTR sequence was carried out as follows. The first PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Beta was recovered and purified from the gel. The purified product was used as a template in the second PCR.<!-- EPO <DP n="22"> -->
<tables id="tabl0006" num="0006"><table frame="topbot"><title>[Table 6]</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">First PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>pCR-ATGbetat (200 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen UTR N3 (SEQ ID NO:20) (10 pmoles)</entry></row><row><entry/><entry>Beta-C (SEQ ID NO:27) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5 min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">Second PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>Purified first PCR product (10 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen UTR N4 (SEQ ID NO:21) (10 pmoles)</entry></row><row><entry/><entry>Beta-C (SEQ ID NO:27) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5 min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup></table></tables></p><p id="p0045" num="0045">The second PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Beta was recovered and purified from the gel. This purified fragment was ligated into pENTR/D-TOPO, which was a vector for incorporation into the silkworm expression vector. The base sequence of the insert was confirmed, and the plasmid was designated pENTR-UTRbeta.</p><heading id="h0016">(3) Obtaining γ-chain cDNA</heading><p id="p0046" num="0046">From the cDNA library, a γ-chain cDNA fragment (hereinafter referred to as Gamma) was amplified under the following reaction conditions. The first PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Gamma was recovered and purified from the gel. The purified product was used as a template in the second PCR.<!-- EPO <DP n="23"> -->
<tables id="tabl0007" num="0007"><table frame="topbot"><title>[Table 7]</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="128mm"/><thead><row><entry valign="top">First PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>Ex Taq</entry></row><row><entry>Template</entry><entry>cDNA Library (Plasmid DNA) Human Liver (TAKARA Code No. 9505) (200 ng)</entry></row><row><entry>Primers</entry><entry>gamma EcoR1 F1 (SEQ ID NO:29) (10 pmoles)</entry></row><row><entry/><entry>gamma Hind3 R1 (SEQ ID NO:30) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>94°C 5 min → (94°C 2 min → 50°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="128mm"/><thead><row><entry valign="top">Second PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>Ex Taq</entry></row><row><entry>Template</entry><entry>Purified first PCR product (10 ng)</entry></row><row><entry>Primers</entry><entry>gamma EcoR1 F2 (SEQ ID NO:31) (10 pmoles)</entry></row><row><entry/><entry>gamma Hind3 R2 (SEQ ID NO:32) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>94°C 5 min → (94°C 2 min → 50°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup></table></tables></p><p id="p0047" num="0047">The second PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Gamma was recovered and purified from the gel, followed by insertion of the purified product into the <i>Eco</i>RI-<i>Hin</i>dIII site of pBluescriptII SK+. The base sequence of the insert was confirmed, and the plasmid was designated pSK-gamma.</p><p id="p0048" num="0048">Subsequently, modification of the signal sequence of Gamma was carried out. The first PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Gamma was recovered and purified from the gel. The purified product was used as a template in the second PCR.<!-- EPO <DP n="24"> -->
<tables id="tabl0008" num="0008"><table frame="topbot"><title>[Table 8]</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">First PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>pSK-gamma (200 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen gamma N1 (SEQ ID NO:33) (10 pmoles)</entry></row><row><entry/><entry>Fibrinogen gamma C1 (SEQ ID NO:34) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="127mm"/><thead><row><entry valign="top">Second PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>Purified first PCR product (10 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen ATG N2 (SEQ ID NO:19) (10 pmoles)</entry></row><row><entry/><entry>Fibrinogen gamma C1 (SEQ ID NO:34) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5 min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25→ 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup></table></tables></p><p id="p0049" num="0049">The second PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Gamma was recovered and purified from the gel. Using Ex Taq, A was added to the 3'-end of the purified second PCR product, and the product was ligated into pCR2.1-TOPO. The base sequence of the insert was confirmed, and the plasmid was designated pCR-ATGgamma.</p><p id="p0050" num="0050">Subsequently, addition of a UTR sequence was carried out as follows. The first PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Gamma was recovered and purified from the gel. The purified product was used as a template in the second PCR.<!-- EPO <DP n="25"> -->
<tables id="tabl0009" num="0009"><table frame="topbot"><title>[Table 9]</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="128mm"/><thead><row><entry valign="top">First PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>pCR-ATGgamma (200 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen UTR N3 (SEQ ID NO:20) (10 pmoles)</entry></row><row><entry/><entry>Fibrinogen gamma C1 (SEQ ID NO:34) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="128mm"/><thead><row><entry valign="top">Second PCR</entry><entry valign="top"/></row></thead><tbody><row><entry>Enzyme</entry><entry>KOD</entry></row><row><entry>Template</entry><entry>Purified first PCR product (10 ng)</entry></row><row><entry>Primers</entry><entry>Fibrinogen UTR N4 (SEQ ID NO:21) (10 pmoles)</entry></row><row><entry/><entry>Fibrinogen gamma C1 (SEQ ID NO:34) (10 pmoles)</entry></row><row><entry>Reaction</entry><entry>96°C 5 min → (96°C 2 min → 55°C 2 min → 72°C 2 min) x 25 → 72°C 7 min → storage at 4°C</entry></row></tbody></tgroup></table></tables></p><p id="p0051" num="0051">The second PCR product was subjected to agarose gel electrophoresis, and the band that was assumed to correspond to Gamma was recovered and purified from the gel. This purified fragment was ligated into pENTR/D-TOPO, which was a vector for incorporation into the silkworm expression vector. The base sequence of the insert was confirmed, and the plasmid was designated pENTR-UTRgamma.</p><heading id="h0017">2. Construction of Human Fibrinogen Expression Vector</heading><p id="p0052" num="0052">Using the GATEWAY system provided by Invitrogen, the fragment cloned in the entry vector pENTR/D-TOPO was subcloned into pXINSECT-DEST38. The inserted fragment was cut out from the resulting plasmid, and then inserted into a known expression vector for the silkworm middle silk gland. Two vectors, that is, a vector that expressed the Bβ chain and a vector that expressed the Aα chain and the γ chain were prepared. The details are described below.</p><heading id="h0018">(1) Bβ Chain-expressing Vector Fibrinogen-β/pMSG1.1R (See Fig. 1)</heading><p id="p0053" num="0053">From pENTR-UTRbeta prepared as described above, the inserted gene was subcloned into pXINSECT-DEST38 using the GATEWAY system. The<!-- EPO <DP n="26"> --> Fibrinogen-β cDNA was cut out from the obtained Fibrinogen-β/pXINSECT by <i>Sma</i>I digestion, and then inserted into the <i>Nru</i>I site of pMSG1.1R, a known vector for transformation of silkworms (<nplcit id="ncit0010" npl-type="s"><text>J Biosci Bioeng 105, 595-603 (2008</text></nplcit>)), to complete construction of Fibrinogen-β/pMSG1.1R for transformation of silkworms (<figref idrefs="f0001">Fig. 1</figref>). The pMSG1.1R vector allows an inserted gene to be expressed in the middle silk gland under the control of the sericin 1 gene promoter Pser1, which functions in the middle silk gland cells. The vector comprises baculovirus-derived hr3 as an enhancer, and as a marker for the expression of transgene, a red fluorescent protein gene DsRed under the control of the promoter 3xP3, which functions in the eyes and the nervous system of a silkworm.</p><heading id="h0019">(2) Aα-chain/γ-chain-expressing vector Fibrinogen-α&amp;γ/pMSG-MG (See Figs. 2 and 3)</heading><p id="p0054" num="0054">From pENTR-UTRalpha and pENTR-UTRgamma prepared as described above, each inserted gene was subcloned into pXINSECT-DEST38 using the GATYEWAY system (Fibrinogen-α/pXINSECT and Fibrinogen-γ/pXINSECT).</p><p id="p0055" num="0055">On the other hand, a gene transfer vector pMSG3.1MG for expression of the two kinds of genes was constructed as described below from pMSG1.1MG, a known vector for transformation of silkworms (<nplcit id="ncit0011" npl-type="s"><text>FEBS Journal 276, 5806-5820 (2009</text></nplcit>)) (<figref idrefs="f0002">Fig. 2</figref>). pMSG1.1MG is a vector prepared from the above-described pMSG1.1R by replacing the transgene expression marker DsRed with a green fluorescent protein gene hMGFP.</p><p id="p0056" num="0056">From pCR4-TOPO vector (PserFLpA/pCR4) comprising a sequence composed of the sericin 1 promoter, an <i>Eco</i>47III restriction site and a fibroin L-chain poly(A) addition signal inserted therein, the insert DNA was cut out with <i>Not</i>I and<!-- EPO <DP n="27"> --> <i>Spe</i>I whose sites were originally contained in the vector, and the obtained insert DNA was blunted. Thereafter, pMSG1.1MG was digested with <i>Asc</i>I (the <i>Asc</i>I site is positioned between the SV40 poly(A) addition signal and hr3) and blunted, and the blunted insert DNA was inserted thereinto. By the above operation, construction of pMSG3.1MG was completed (<figref idrefs="f0002">Fig. 2</figref>).</p><p id="p0057" num="0057">The Fibrinogen-α cDNA was cut out from Fibrinogen-α/pXINSECT by <i>Sma</i>I digestion, and the cDNA was inserted into the <i>Nru</i>I site of the pMSG3.1MG vector prepared as described above to obtain Fibrinogen-α/pMSG3.1MG. The Fibrinogen-y cDNA was cut out from Fibrinogen-γ/pXINSECT, and the cDNA was inserted into the <i>Eco</i>47III site of Fibrinogen-α/pMSG3.1MG, thereby completing construction of Fibrinogen-α&amp;γ/pMSG3.1MG (<figref idrefs="f0003">Fig. 3</figref>).</p><heading id="h0020">3. Preparation of Transgenic Silkworm</heading><heading id="h0021">(1) Preparation of Bβ-introduced Silkworm</heading><p id="p0058" num="0058">The gene transfer vector constructed as described above, Fibrinogen-β/pMSG1.1R, was purified by cesium chloride ultracentrifugation, and mixed with a helper plasmid pHA3PIG (<nplcit id="ncit0012" npl-type="s"><text>Nat. Biotechnol. 18, 81-84 (2000</text></nplcit>)) such that the plasmid ratio was 1:1. The resulting mixture was concentrated by ethanol precipitation, and dissolved in an injection buffer (0.5 mM phosphate buffer pH 7.0, 5 mM KCl) such that the concentration of each of the gene transfer vector and pHA3PIG became 200 µg/ml to obtain a DNA solution for injection into eggs. This DNA solution was microinjected into silkworm eggs (silkworm embryos) at the preblastoderm stage, i.e. 2 to 8 hours after spawning, in a liquid amount of about 15 to 20 nl/egg, and the eggs were incubated at 25°C. From a total of 3,032 eggs subjected to the injection, 600 eggs were hatched. By crossing reproductive adults obtained therefrom, 112 groups of F1 egg masses were obtained. F1 egg masses on Day 5 to 6 after spawning were<!-- EPO <DP n="28"> --> observed under a fluorescence stereoscopic microscope to select eggs in which expression of the marker gene, i.e. red fluorescence from the eyes and the nervous system, could be seen. Seven groups of egg masses containing eggs of Bβ-expressing silkworms were obtained. These eggs were allowed to hatch and the larvae were grown. As a result, transgenic silkworms originated from a plurality of egg masses could be normally grown to be reproductive adults. The adults were crossed with wild-type silkworms to obtain 6 strains of Bβ-introduced silkworms.</p><heading id="h0022">(2) Preparation of Aα/γ-introduced Silkworm</heading><p id="p0059" num="0059">In the same manner as described above, the gene transfer vector Fibrinogen-α&amp;γ/pMSG3.1MG was purified, and microinjected into silkworm eggs together with the helper plasmid. From a total of 3,336 eggs subjected to the injection, 1,050 eggs were hatched. By crossing reproductive adults obtained therefrom, 233 groups of F1 egg masses were obtained. Eggs were selected based on green fluorescence from the eyes and the nervous system, and 17 groups of egg masses containing eggs of Aα/γ-expressing silkworms were obtained. Normally grown adults were crossed with wild-type silkworms to obtain 14 strains of Aα/γ-introduced silkworms.</p><heading id="h0023">(3) Confirmation of Expression of Fibrinogen Subunits</heading><p id="p0060" num="0060">The Bβ-introduced silkworm strain and the Aα/γ-introduced silkworm strain obtained as described above were investigated for secretion of the proteins of interest into their cocoons by Western blotting. The cocoons were cut and immersed in a buffer containing 8 M urea (8 M urea, 50 mM Tris buffer, pH 8.0), and heated at 80°C for 5 minutes, followed by centrifugation to obtain a supernatant, which was then subjected to Western blotting. A part of the results is shown in <figref idrefs="f0004">Fig. 4</figref>. Secretion of both Aα chain and γ chain into the cocoons could be confirmed in the Aα/γ-introduced silkworms. However, the Bβ chain could not be detected in the<!-- EPO <DP n="29"> --> cocoons of the Bβ-introduced silkworms.</p><p id="p0061" num="0061">In order to investigate whether the Bβ chain was expressed as a protein in the silk gland cells, expression analysis was carried out using silk glands of fifth instar larvae. The silk glands were collected from fifth instar larvae of wild-type and Bβ-introduced silkworms, and subjected to extraction with 1xTBS. After centrifugation, the resulting supernatant was obtained as a soluble fraction. The precipitate was further subjected to extraction with 1xSDS-PAGE sample buffer to obtain an insoluble fraction. The fractions were electrophoresed and Western blotting was carried out to find that the signal for the Bβ chain was detected in the insoluble fraction (<figref idrefs="f0004">Fig. 5</figref>). Thus, it could be confirmed that, in Bβ-introduced silkworms, the Bβ chain was normally synthesized but stayed inside the silk gland cells.</p><heading id="h0024">(4) Preparation of Aα/Bβ/γ-introduced Silkworm</heading><p id="p0062" num="0062">Bβ-introduced silkworms, in which secretion of the Bβ chain into the cocoons could not be observed, were crossed with Aα/γ-introduced silkworms, in which secretion of the Aα chain and the γ chain into the cocoons could be observed, to obtain a plurality of strains of Aα/Bβ/γ-introduced silkworms. These plurality of strains of silkworms were subjected to irradiation with the excitation light at the egg or larva stage to confirm that yellow fluorescence as a result of combination of red fluorescence and green fluorescence could be observed. The proteins contained in the cocoons of these silkworms were extracted in the same manner as described above, and subjected to SDS-polyacrylamide gel electrophoresis, followed by observation by CBB staining. As a result, a clear band could be detected for all of the Aα chain, Bβ chain and γ chain (<figref idrefs="f0005">Fig. 6</figref>).</p><heading id="h0025">4. Use of Transcription Factor for Increasing Expression Level of Fibrinogen</heading><!-- EPO <DP n="30"> --><p id="p0063" num="0063">It is known that the activity of the sericin promoter largely increases in cases where the sericin promoter is used in combination with hr3, which is an enhancer derived from a baculovirus (BmNPV), and the IE1 gene, which is a transactivator similarly derived from BmNPV (see <patcit id="pcit0008" dnum="JP4271122B"><text>JP 4271122 B</text></patcit>). This technique has been utilized for expression of a recombinant protein in silkworms, and a transgenic silkworm strain that expresses IE1 protein in the middle silk gland is known (<nplcit id="ncit0013" npl-type="s"><text>FEBS Journal 276, 5806-5820 (2009</text></nplcit>), <nplcit id="ncit0014" npl-type="s"><text>Biotechnol Bioeng 106, 860-870 (2010</text></nplcit>)). Using the known IE1-expressing silkworm, we attempted to enhance the expression level of the transgenes in the Aα/Bβ/γ-introduced silkworm.</p><p id="p0064" num="0064">The IM1 silkworm is a silkworm into which IE1 has been introduced under the control of the sericin 1 promoter, and the silkworm shows high expression of transcription factor IE1 (<nplcit id="ncit0015" npl-type="s"><text>Biotechnol Bioeng 106, 860-870 (2010</text></nplcit>)). Aα/Bβ/γ-introduced silkworms prepared as described above were crossed with IM1 silkworms to obtain Aα/Bβ/γ x IM silkworms, and the cocoons of the Aα/Bβ/γ x IM silkworms were obtained. The expression level of each subunit (content of each subunit in the cocoon filament) in the obtained cocoons was investigated. The results showed that the expression level of fibrinogen largely increased, but the cocoon weight decreased to about 30 to 40% (Table 10 and <figref idrefs="f0006">Fig. 7</figref>).
<tables id="tabl0010" num="0010"><table frame="all"><title>[Table 10]</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="37mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><thead><row><entry valign="top">Silkworm strain</entry><entry valign="top">Cocoon weight</entry></row></thead><tbody><row><entry>Wild type</entry><entry>89.6 mg</entry></row><row><entry>β42-3 x α/γ103-10</entry><entry>84.2 mg</entry></row><row><entry>β64-1 x α/γ106-2</entry><entry>78.8 mg</entry></row><row><entry>β42-3 x α/γ103-10 x IM</entry><entry>34.0 mg</entry></row><row><entry>β64-1 x α/γ106-2 x IM</entry><entry>24.7 mg</entry></row></tbody></tgroup></table></tables></p><p id="p0065" num="0065">The IE1 silkworm is a strain showing a lower expression level of IE1 than the<!-- EPO <DP n="31"> --> IM1 silkworm (<nplcit id="ncit0016" npl-type="s"><text>FEBS Journal 276, 5806-5820 (2009</text></nplcit>)). Crossing with IE1 silkworms was carried out to obtain Aα/Bβ/γ x IE silkworms, and the cocoons of the Aα/Bβ/γ x IE silkworms were obtained. The expression level of each subunit (content of each subunit in the cocoon filament) in the obtained cocoons and the cocoon weight were investigated. Decrease in the cocoon weight could be avoided. The expression level of fibrinogen was higher than that in Aα/Bβ/γ silkworms, but lower than that in Aα/Bβ/γ x IM silkworms (Table 11 and <figref idrefs="f0007">Fig. 8</figref>).
<tables id="tabl0011" num="0011"><table frame="all"><title>[Table 11]</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="35mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><thead><row><entry valign="top">Silkworm strain</entry><entry valign="top">Cocoon weight</entry></row></thead><tbody><row><entry>Wild type</entry><entry>89.6 mg</entry></row><row><entry>β42-3 x α/γ 106-4</entry><entry>86.4 mg</entry></row><row><entry>β42-3 x α/γ106-4 x IE</entry><entry>68.2 mg</entry></row><row><entry>β42-3 x α/γ106-4 x IM</entry><entry>34.0 mg</entry></row></tbody></tgroup></table></tables></p><p id="p0066" num="0066">When comparing Aα/Bβ/γ x IM silkworms and Aα/Bβ/γ x IE silkworms, the former Aα/Bβ/γ x IM silkworms were found to show higher production of fibrinogen in terms of the total production per cocoon. Thus, crossing with an IM1 silkworm, which highly expresses the transactivator, is advantageous for production of fibrinogen.</p><heading id="h0026">5. Investigation of Conditions for Extraction of Recombinant Fibrinogen from Cocoon</heading><p id="p0067" num="0067">In order to efficiently extract fibrinogen from the cocoons of Aα/Bβ/γ-introduced silkworms, extraction conditions were investigated.</p><p id="p0068" num="0068">Using the cocoons of Aα/Bβ/γ-introduced silkworms into which the transactivator had not been introduced, the conditions for extraction of fibrinogen were investigated. The cocoons were cut and immersed in a buffer to perform<!-- EPO <DP n="32"> --> extraction treatment. Since extraction with PBS was difficult, buffers with various compositions containing NaCl, a surfactant and/or the like were used for the investigation as shown in <figref idrefs="f0008">Fig. 9</figref>. It is desirable to carry out the extraction while avoiding extraction of sericin as much as possible in consideration of subsequent purification steps, and it is desirable to make the urea concentration lower in order to suppress denaturation. In view of these, it was considered that the most preferred condition is one described as No. 8 (2 M urea, 50 mM Tris-HCl (pH 7.5), 1% Triton X-100; extraction at 4°C for 16 hours) in <figref idrefs="f0008">Fig. 9</figref>.</p><p id="p0069" num="0069">Using the cocoons of Aα/Bβ/γ x IM silkworms into which the transactivator had been introduced, the conditions for extraction of fibrinogen were investigated as shown in <figref idrefs="f0009">Fig. 10</figref> (extraction was carried out at 4°C for 16 hours in all cases). Since the expression level of fibrinogen was higher than that in the Aα/Bβ/γ silkworms used in the above-described investigation, fibrinogen could be efficiently extracted under milder conditions, and the extraction could be sufficiently carried out even when the concentration of Triton X-100 was lowered to 0.1%.</p><p id="p0070" num="0070">The cocoons of Aα/Bβ/γ x IM silkworms were subjected to extraction with 6 M urea, 50 mM Tris-HCl (pH 7.5), and the extracts were electrophoresed under nonreducing conditions (without 2-mercaptoethanol). Although a clear band could not be formed due to the large molecular weight of the protein, it was considered from its size that the protein was a hexamer (data not shown).</p><heading id="h0027">6. Confirmation of Coagulation Activity of Fibrinogen</heading><p id="p0071" num="0071">Whether human fibrinogen produced in a silkworm could react with thrombin to cause coagulation (to form fibrin clot) was investigated.</p><p id="p0072" num="0072"><!-- EPO <DP n="33"> --> Cocoons of β42-3 x α/γ106-2 x IM were subjected to extraction with 2 M urea, 50 mM Tris-HCl (pH7.5) and 0.1% Triton X-100 at 4°C overnight. By ultrafiltration (Amicon Ultra-15 10,000 NMWL, Millipore), the extract was concentrated from 15 ml to 400 µl. Subsequently, 15 ml of 100 mM Tris-HCl (pH8.0), 200 mM NaCl, 500 nM CaCl<sub>2</sub> was added thereto, and the resulting mixture was concentrated again to 400 µl (buffer exchange). At this stage, a part of the proteins was insolubilized to cause precipitation. After removal of the precipitate, thrombin (Calbiochem) was added to the obtained liquid to a final concentration of 10 U/ml, and the resulting mixture was incubated at 37°C for 1 hour. As a result, viscosity of the liquid increased to an extent where, when the liquid was sucked into a pipette, the liquid hardly dropped from the tip of the pipette. Thus, the coagulation activity of the fibrinogen produced by the silkworm could be confirmed.<!-- EPO <DP n="34"> -->
<img id="ib0001" file="imgb0001.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="35"> -->
<img id="ib0002" file="imgb0002.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="36"> -->
<img id="ib0003" file="imgb0003.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="37"> -->
<img id="ib0004" file="imgb0004.tif" wi="154" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="38"> -->
<img id="ib0005" file="imgb0005.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="39"> -->
<img id="ib0006" file="imgb0006.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="40"> -->
<img id="ib0007" file="imgb0007.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="41"> -->
<img id="ib0008" file="imgb0008.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="42"> -->
<img id="ib0009" file="imgb0009.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="43"> -->
<img id="ib0010" file="imgb0010.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="44"> -->
<img id="ib0011" file="imgb0011.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="45"> -->
<img id="ib0012" file="imgb0012.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="46"> -->
<img id="ib0013" file="imgb0013.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="47"> -->
<img id="ib0014" file="imgb0014.tif" wi="149" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="48"> -->
<img id="ib0015" file="imgb0015.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="49"> -->
<img id="ib0016" file="imgb0016.tif" wi="134" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="50"> -->
<img id="ib0017" file="imgb0017.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="51"> -->
<img id="ib0018" file="imgb0018.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="52"> -->
<img id="ib0019" file="imgb0019.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="53"> -->
<img id="ib0020" file="imgb0020.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="54"> -->
<img id="ib0021" file="imgb0021.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="55"> -->
<img id="ib0022" file="imgb0022.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="56"> -->
<img id="ib0023" file="imgb0023.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="57"> -->
<img id="ib0024" file="imgb0024.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="58"> -->
<img id="ib0025" file="imgb0025.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="59"> -->
<img id="ib0026" file="imgb0026.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="60"> -->
<img id="ib0027" file="imgb0027.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="61"> -->
<img id="ib0028" file="imgb0028.tif" wi="129" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="62"> -->
<img id="ib0029" file="imgb0029.tif" wi="130" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="63"> -->
<img id="ib0030" file="imgb0030.tif" wi="149" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="64"> -->
<img id="ib0031" file="imgb0031.tif" wi="149" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="65"> -->
<img id="ib0032" file="imgb0032.tif" wi="154" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="66"> -->
<img id="ib0033" file="imgb0033.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="67"> -->
<img id="ib0034" file="imgb0034.tif" wi="154" he="31" img-content="dna" img-format="tif"/></p></description><claims mxw-id="PCLM56982921" lang="EN" load-source="patent-office"><!-- EPO <DP n="68"> --><claim id="c-en-0001" num="0001"><claim-text>A transgenic silkworm which expresses fibrinogen subunit Aα, Bβ and γ chains in silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The transgenic silkworm according to claim 1, which expresses said subunits in middle silk gland cells and produces fibrinogen in the sericin layer of the cocoon filament.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The transgenic silkworm according to claim 2, wherein the Aα-chain gene, Bβ-chain gene and y-chain gene are each functionally linked to a promoter of the sericin gene.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The transgenic silkworm according to claim 3, wherein the Aα-chain gene, Bβ-chain gene and γ-chain gene have been introduced in combination with an enhancer(s).</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>The transgenic silkworm according to claim 4, wherein said enhancer is hr3 derived from a baculovirus.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>The transgenic silkworm according to any one of claims 3 to 5, wherein the Aα-chain gene, Bβ-chain gene and γ-chain gene have been introduced in combination with a transactivator(s).</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>The transgenic silkworm according to claim 6, wherein said transactivator is transcription factor IE1 derived from a baculovirus.</claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>A silkworm cocoon produced by the transgenic silkworm according to any one of claims 1 to 7, said silkworm cocoon comprising fibrinogen having coagulation activity.</claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>A method for producing fibrinogen, said method comprising recovering fibrinogen from the cocoon of the transgenic silkworm according to claim 8.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>The method according to claim 9, said method comprising: immersing the cocoon filament of said silkworm in a buffer comprising 1 to 4 M urea, 25 to 100<!-- EPO <DP n="69"> --> mM Tris-HCl (pH 6.5 to 8.5), 0.01 to 2.0% surfactant and 0 to 0.25 M NaCl; and recovering fibrinogen eluted into said buffer.</claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>The method according to claim 10, wherein said surfactant is at least one selected from the group consisting of polyoxyethylene octylphenyl ether, polyethylene glycol-p-octylphenyl ether and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate.</claim-text></claim><claim id="c-en-0012" num="0012"><claim-text>A method for preparing a transgenic silkworm that produces fibrinogen having coagulation activity in the cocoon filament, said method comprising: introducing the fibrinogen subunit Aα, Bβ and γ genes each functionally linked to a promoter that functions in silk gland cells into silkworms; and selecting a silkworm that expresses the Aα, Bβ and γ chains in silk gland cells.</claim-text></claim><claim id="c-en-0013" num="0013"><claim-text>The method according to claim 12, wherein said silk gland is a middle silk gland and said promoter is a promoter of the sericin gene.</claim-text></claim><claim id="c-en-0014" num="0014"><claim-text>The method according to claim 12 or 13, wherein the Aα gene, Bβ gene and γ gene are introduced together with an enhancer(s).</claim-text></claim><claim id="c-en-0015" num="0015"><claim-text>The method according to claim 14, wherein said enhancer is hr3 derived from a baculovirus.</claim-text></claim><claim id="c-en-0016" num="0016"><claim-text>The method according to any one of claims 12 to 15, further comprising introducing a transactivator(s) to a silkworm.</claim-text></claim><claim id="c-en-0017" num="0017"><claim-text>The method according to claim 16, wherein said transactivator is transcription factor IE1 derived from a baculovirus.</claim-text></claim><claim id="c-en-0018" num="0018"><claim-text>The method according to any one of claims 12 to 17, wherein the three subunit genes are introduced into a silkworm by crossing a first silkworm with a second silkworm, said first silkworm being prepared by introducing a vector comprising any one of the Aα gene, the Bβ gene and the γ gene downstream of a promoter that functions in silk gland cells, said second silkworm being prepared by introducing a vector comprising each of the other two genes downstream of a<!-- EPO <DP n="70"> --> promoter that functions in silk gland cells.</claim-text></claim><claim id="c-en-0019" num="0019"><claim-text>The method according to claim 18, wherein a first silkworm prepared by introducing a vector comprising the Bβ gene is crossed with a second silkworm prepared by introducing a vector comprising the Aα gene and the γ gene.</claim-text></claim></claims><drawings mxw-id="PDW16671237" load-source="patent-office"><!-- EPO <DP n="71"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="140" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="72"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="138" he="230" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="73"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="161" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="74"> --><figure id="f0004" num="4,5"><img id="if0004" file="imgf0004.tif" wi="106" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="75"> --><figure id="f0005" num="6"><img id="if0005" file="imgf0005.tif" wi="126" he="205" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="76"> --><figure id="f0006" num="7"><img id="if0006" file="imgf0006.tif" wi="122" he="217" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="77"> --><figure id="f0007" num="8"><img id="if0007" file="imgf0007.tif" wi="130" he="90" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="78"> --><figure id="f0008" num="9"><img id="if0008" file="imgf0008.tif" wi="97" he="213" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="79"> --><figure id="f0009" num="10"><img id="if0009" file="imgf0009.tif" wi="102" he="233" img-content="drawing" img-format="tif"/></figure></drawings><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="165" he="232" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="165" he="232" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
